Comparative Effectiveness and Safety of Original Gabapentin and Generic Gabapentin in Treating Patients with Neuropathic Pain at Siriraj Hospital, Bangkok, Thailand

Authors

  • Rungsan Chaisewikul Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Ratikorn Saejong Division of Clinical Epidemiology, Office for Research and Development, Faculty of Medicine Siriraj Hospital
  • Sasima Tongsai Division of Clinical Epidemiology, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Visanu Thamlikitkul Division of Clinical Epidemiology, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University

Keywords:

Gabapentin, generic gabapentin, neuropathic pain

Abstract

Background: Neuropathic pain (NP) develops as a consequence of a lesion or disease affecting the somatosensory system. Patients with severe NP usually suffer from pain and may need many treatment options. Drugs frequently prescribed for treatment of NP include amitriptyline, carbamazepine, gabapentin, and pregabalin.

Objective: To compare the effectiveness and safety between original gabapentin (Neurontin® ) and generic gabapentin (Gabapentin Sandoz® ) in treating patients with NP at Siriraj Hospital.

Methods: The study was a non-inferiority retrospective study. The medical records of the eligible patients who received gaba- pentin for NP were retrieved and all relevant data were extracted and recorded. Effectiveness and safety of both formulations of gabapentin were analyzed.

Results: There were 356 NP patients who received original gabapentin and 356 NP patients who received generic gabapentin in which 105 patients received only generic gabapentin and 251 patients had received original gabapentin prior to receiving generic gabapentin. Demographic and underlying conditions of the patients leading to receiving gabapentin were not significantly different. Favorable clinical responses were observed in 91.0% (95% CI: 87.6, 93.6) and 95.2% (95% CI: 92.5, 97.0) of the patients who received original gabapentin and generic gabapentin, respectively. Effectiveness of generic gabapentin was not inferior to that of original gabapentin. Incidences of adverse events in the patients who received only original gabapentin and generic gabapentin were 29.2% (95% CI: 24.7, 34.1) and 28.6% (95% CI: 20.8, 37.9) respectively (p-value = 0.996).

Conclusion: The effectiveness and safety of generic gabapentin and original gabapentinin for treatment of patients with NP at Siriraj Hospital were comparable.

Downloads

Published

31-07-2020

How to Cite

Chaisewikul, R. ., Saejong, R. ., Tongsai, S., & Thamlikitkul, . V. (2020). Comparative Effectiveness and Safety of Original Gabapentin and Generic Gabapentin in Treating Patients with Neuropathic Pain at Siriraj Hospital, Bangkok, Thailand. Siriraj Medical Journal, 64(6), 172–177. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/244191

Issue

Vol. 64 No. 6 (2012): Nov-Dec

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.